Abstract In elucidating the role of pharmacodynamic efficacy at D 3 receptors in therapeutic effectiveness of dopamine receptor agonists, the influence of study system must be understood. 
Introduction
The D 2 -like family of dopamine receptors is a major drug target for treatment of motor and neuropsychiatric disorders [1, 2] . The D 3 member of this family in particular, is associated with regulation of motivation/reward, mood, cognition and motor function, and is expressed throughout the limbic forebrain and basal ganglia, albeit at lower levels than D 2 receptors [3] [4] [5] . D 3 receptors are promising targets for treatment of drug abuse, schizophrenia, attention deficit hyperactivity disorders and motor diseases such as Parkinson's disease [1, [6] [7] [8] . Despite the promise of therapeutic targeting of this receptor, development of ligands with high selectivity for D 3 over other D 2 -like receptors and which possess a range of intrinsic efficacies, has been challenging. In order to elucidate the role of pharmacodynamic efficacy at D 3 receptors in therapeutic effectiveness, the influence of study system, such as cell lines heterologously expressing the receptor versus native systems (e.g., striatum), must be understood.
D 3 receptors are coupled to the activation of mainly G i/o family G proteins [9, 10] . G protein activation by receptors promotes exchange of GDP for GTP, which can be quantified in the GTPc 35 S binding assay [9, 11] . It is well known that G protein-coupled receptor (GPCR) ligands can display partial agonism in this assay with brain tissue when the receptor number is low compared with available G proteins, whereas the same ligands can become full agonists in cells overexpressing GPCRs such that the receptor number is high compared with available G protein [11] [12] [13] [14] [15] [16] [17] . Even though most high efficacy agonists maximally stimulate GTPc 35 S binding in these cell lines, their intrinsic efficacy may vary as shown by the varying levels of receptor reserve depending on the activating ligand [12, 17] .
The work described here examined the intrinsic efficacy of two synthetic agonists at D 2 and D 3 dopamine receptors. These compounds are two related hybrid tetrahydrobenzo [d] thiazole based arylpiperazines developed in our earlier work [18, 19] : D-264 and D-301. Both compounds contain the tetrahydrobenzo[d]thiazole moiety, connected through a (propyl substituted)N-ethyl linker with a piperazine biphenyl moiety (D-264) or a piperazine isoquinolin moiety (D-301) (Fig. 1) . The tetrahydrobenzo [d] thiazole portion is thought to bind to the primary binding pocket of the dopamine receptor, whereas the aryl piperazine moiety likely binds an accessory binding site(s) [20] . Both compounds appeared to be full agonists relative to DA. We chose D-264 as one of the compounds for study since it not only displayed preferential D 3 potency but also exhibited efficacious in vivo activity including potent neuroprotection [19, 21] . D-301 was selected because the compound exhibited high potency and very high selectivity for D 3 receptors [18] . Another reason for selecting these two compounds is their structural diversity in the substitution of piperazine ring of the compounds such that D-301 has an isoquinoline moiety as opposed to presence of biphenyl substitution in the case of D-264. This might potentially impact interaction at the accessory binding sites of the receptors which might lead to production of differential receptors activation.
Two approaches were taken in this work to study potential differences in intrinsic efficacy of D-264 and D-301. First, the ability of the compounds to stimulate GTPc 35 S binding was determined in assays with brain tissue from either wild-type (WT) or D 2 dopamine receptor knock-out (KO) mice [22] . In WT mice, both D 2 and D 3 receptors can contribute to G protein activation, whereas in D 2 KO mice, the D 2 component has been removed. In this scenario, a difference in maximal activation between the two compounds suggests a difference in intrinsic efficacy at the level of D 3 receptor-mediated G protein activation. In a second approach, cell lines expressing only D 2 or D 3 receptors were used to determine intrinsic efficacy by assessing ligand-stimulated GTPc 35 S binding and competition for [ 3 H]spiperone binding under identical conditions. In this system, the ratio of binding K i to G protein activation EC 50 values, combined with maximal activation values (E max ), was used to evaluate the intrinsic efficacy of ligands [12, 23] . Because of the reportedly greater efficiency of D 3 receptor coupling to G o relative to G i [24] and the fact that G o is highly expressed in the brain [25] , experiments were conducted in dopamine receptor-expressing cells both in the absence and presence of transiently expressed Ga o1 . The results from the two approaches combined indicate that D-301 has a greater intrinsic efficacy at D 3 receptors than D-264, whereas the two compounds acted on D 2 receptors with similar intrinsic efficacy. and incubated on ice for a total of 30 min with 10-s vortexing every 10 min. After centrifugation at 20, 000 g for 15 min at 4°C, the supernatant was collected and protein concentration was determined by a Bio-Rad DC protein assay kit. For western blot analysis, equal amounts of protein (30-60 lg per lane) were loaded on 10 % Trisglycine polyacrylamide gel. Membranes were probed with rabbit anti-Ga o1 antibody (GNAO1, Proteintech Group, Chicago, IL) and rabbit anti-b-actin (Sigma-Aldrich). The target protein bands were visualized by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech, Buckinghamshire, England) and quantified using Image-J (downloaded from website of National Institute of Heath). The integrated density value (IDV) for the protein Ga o1 was normalized with that for loading control b-actin. In each experiment the ratio of normalized IDV for Ga o1 protein with transient transfection over that without transient transfection was calculated.
Materials and Methods

Materials and Animals
Cell-Free Membrane Preparation
Confluent cells were gently washed with ice-cold Dulbecco's Phosphate-Buffered Saline (DPBS) (without calcium and magnesium salts) and then lysed with 3 mL icecold lysis buffer (50 mM Tris-HCl and 1 mM EDTA, pH = 7.4). Cell lysate was transferred to a Beckman polycarbonate thick-wall centrifuge tube and centrifuged at 35,000g for 15 min at 4°C. The resultant pellet was homogenized with a Brinkmann Polytron (Brinkmann Instruments, Westbury, NY) at setting 6 for 15 s in the above lysis buffer and centrifuged again at 35,000g for 15 min at 4°C. The final pellet containing crude cell-free membranes was suspended in the following assay buffer, for CHO-hD 2 : 20 mM HEPES (pH = 7.4), 10 mM MgCl 2 , 150 mM NaCL, 0.2 mM EGTA, 0.001 % BSA, 3 lM GDP; and for CHO-hD 3 : 20 mM HEPES (pH = 7.4), 3 mM MgCl 2 , 100 mM NaCL, 0.2 mM EGTA, 0.001 % BSA, 6 lM GDP. The resuspended membrane preparations were kept in ice.
For mouse tissues, mice were euthanized at Oregon Health and Science University, and brains were frozen at -30°C in 2-methylbutane as previously described. Brains were shipped on dry ice by overnight express to Virginia Commonwealth University, where they were stored at -80°C until use. On the day of each assay, one brain each from D 2 KO and wild-type mice were thawed, and the caudate-putamen (dorsal striatum) and nucleus accumbens (ventral striatum) were dissected on ice. The tissue was homogenized in 50 mM Tris-HCl (pH 7.4), 3 mM MgCl 2 and 1 mM EGTA, pH 7.4, and centrifuged at 48,0009g for 10 min. The supernatant was discarded, and the pellet resuspended in 50 mM Tris-HCl (pH 7.4), 3 mM MgCl 2 , 0.1 mM EGTA and 100 mM NaCl, the volume was normalized to obtain equal protein concentrations between samples, and membranes were pre-incubated for 10 min at 30°C with 30 mU/ml adenosine deaminase to inactivate endogenous adenosine prior to assay. Because GDP is sensitive to temperature and light, GDP was only retrieved and added to the cell suspension (3 lM unlabeled GDP for CHO-D 2 and 6 lM for CHO-D 3 in the assay) just before initiating the binding experiment. Different concentrations of test compounds were first pre-incubated with cell suspension for 15 min at 30°C. After addition of [ 35 S]GTPcS at 0.1 nM (final concentration), the binding assay was continued for another 45 min at 30°C. Nonspecific binding was defined with 10 lM unlabeled GTPcS. Assays were terminated by filtration with ice-cold lysis buffer through a glass fiber filtermat B in the Brandel-96 cell harvester. The filtermat was dried under hot air and, after addition of 10 ml of Betaplate Scint (PerkinElmer), counted for radioactivity in a Microbeta liquid scintillation counter (PerkinElmer).
[ 35 S]GTPcS Binding in Mouse Striatum
Membranes were prepared from dissected caudate-putamen (dorsal striatum) and nucleus accumbens (ventral striatum), and ligand-stimulated [ 35 S]GTPcS binding was conducted essentially as described [28] . Briefly, membranes (3-4 lg protein) was incubated with 30 lM GDP, 0.1 nM [ 35- S]GTPcS and varying ligand concentrations in 50 mM Tris-HCl (pH 7.4), 3 mM MgCl 2 , 0.1 mM EGTA, 100 mM NaCl and 3 mU/ml adenosine deaminase, 0.5 ml final volume, for 90 min at 30°C. The incubation was terminated by rapid filtration through GF/B glass fiber filters and washed three times with ice-cold 50 mM Tris-HCl (pH 7.4). Bound radioactivity was determined by liquid scintillation spectrophotometry after overnight extraction of the filters in scintillation fluid. Non-specific binding was determined in the presence of 20 lM unlabeled GTPcS, and basal binding was determined in the absence of agonist. All assays were performed in triplicate, and data were analyzed as specific binding. 
The error in the K i /EC 50 ratio was computed from the propagation of the errors in the K i and EC 50 ([32] , Eq. 1a therein); likewise these errors along with that in E max, drug were propagated for calculating the error in intrinsic efficacy Statistical tests involving values for the K i /EC 50 ratio and intrinsic efficacy were performed by inputting the mean, SEM, and smallest group size (conservative approach) in the given data set, into the Instat program which is part of the Graphpad software; the smallest n varied between 3 and 7 depending on the data set. The accepted level of significance was 0.05. Tests were twotailed except in the case of determining whether the K i / EC 50 ratio or intrinsic efficacy was different from unity, because receptor reserve would drive such values only in the direction of [1 (i.e., representing a one-tailed case).
Results
D 2 KO Mice
To determine the contribution of D 3 receptors to agoniststimulated G-protein activation in mouse striatum by D-264 and D-301, stimulation of [
35 S]GTPcS binding was examined in membranes prepared from caudate-putamen (Fig. 2a, c) and nucleus accumbens (Fig. 1b, d) [33] , and previous reports emphasize the importance of Ga o in D 3 receptor-G-protein coupling [9, [34] [35] [36] [37] , Ga o1 was transiently co-expressed in CHO cells expressing either D 2 or D 3 . Although our CHO cell lines were found to express endogenous Ga o1 , detectable with GNAO1 antibody (Fig. 3, bottom panel) , transient transfection with exogenous Ga o1 approximately doubled the total Ga o1 expression (Fig. 3, top panel) 
Discussion
The present study revealed intrinsic efficacy differences for D 3 The finding that D-264 produced small but significant stimulation of [ 35 S]GTPcS binding in caudate-putamen but not in nucleus accumbens was somewhat unexpected, because D 3 receptor levels are reportedly greater in the latter region in rats [4] . It is possible that our dissections also included portions of the Islands of Calleja, where D 3 receptors are also highly expressed [4] . Moreover, autoradiographic studies in post-mortem human brain also showed relatively high D 3 receptor levels in the more ventral aspects of both the caudate and putamen [5] . It is also possible that D 3 receptors are more efficiently coupled [11, 12, 14, 41] . However, heterologous receptor expression is generally driven by efficient viral promoters and is therefore often higher than in native tissues. The relationship between receptor expression levels and ligand efficacy determinations are well established; in the mu opioid receptor example we previously observed that MOR expression levels were approximately 5-fold greater in transfected CHO cells than in rat thalamus [11, 12] . In the current study, D 2 and D 3 receptor B max values were approximately 2 to 4-fold and 135-fold, respectively, greater than those reported in rodent striatum [22, 42, 43] . Although receptor B max comparisons between brain and cell lines must be viewed with caution because presumably not every cell type in a dissected brain region expresses the receptor of interest, it seems likely that these receptors, especially D 3 , are over-expressed in our CHO cell models relative to naturally occurring levels in the striatum. This is particularly true when taking into account the ratio of receptors to activated G i/o proteins, because activated G i/o protein levels tend to be much greater in the brain [11] . One should, however, keep in mind that compensatory changes in dopamine receptor expression-especially 'D2 high' receptor expression-are well documented in dopamine receptor knockout animals [44] . All considerations taken together, one expects receptor reserve for G protein activation by high efficacy ligands to be more likely present in transfected cell models. Therefore, we determined the intrinsic efficacy of ligand-stimulated G protein activation by determining receptor binding K i to G protein activation EC 50 values [12, 23] Another major difference between the CHO cell models and mouse striatum, besides D 3 receptor expression levels, is the high expression of Ga o1 in striatum [25] compared to its reported absence in CHO cells [33] . We therefore examined the relative intrinsic efficacies of D-264 and [24, 45] , which are the major Ga i isoforms in CHO cells [46] . Moreover, differential activation of Ga o versus Ga i isoforms by D 2 -like receptors can also be ligand-dependent [47, 48] . In the present study, the intrinsic efficacies of both D-264 and D-301 were not significantly affected by exogenous Ga o 1 expression in D 2 -expressing cells. Exogenous Ga o1 -expression appeared to enhance the intrinsic efficacy of D-264 and D-301 (by *50 %) in D 3 -expressing cells, such that D-264 gained receptor reserve indicated by a K i /EC 50 value greater than unity. However, there was not a statistically significant increase in the calculated intrinsic efficacy of either ligand and only D-301 exhibited an intrinsic efficacy value greater than unity. Nonetheless, only in the presence of exogenous Ga o1 did the intrinsic efficacy of D-301 at D 3 receptors approach that of DA, whereas this ligand retained very low intrinsic efficacy in D 2 -expressing cells regardless of the presence or absence of exogenous Ga o1 . Examination of the receptor-binding data suggests that the major explanation for this convergence of intrinsic efficacy values between D-301 and DA was that the binding K i values were differentially affected by exogenous Ga o1 expression. The D-301 affinity decreased in exogenous Ga o1 expressing cells whereas the DA affinity increased, and the EC 50 values of both ligands were unaffected. Although the potency of D-264 to activate G-proteins was significantly increased by exogenous Ga o1 expression in D 3 -expressing cells, the E max value was moderately decreased so there was no significant effect of exogenous Ga o1 expression on intrinsic efficacy of this ligand. Thus, the major effect of exogenous Ga o1 expression in D 3 -expressing cells was enhancement of the binding affinity of DA but not of the synthetic ligands, such that the intrinsic efficacy values became more similar between DA and the synthetic ligands (especially D-301) in exogenous Ga o1 -expressing cells.
While the precise mechanisms underlying the relative intrinsic efficacy differences between D-301 and D-264 at D 3 receptors remains to be elucidated, one relevant conclusion from these CHO cell studies is that exogenous Ga o1 expression did not affect the ratio of intrinsic efficacies of D-301:D-264 at D 3 receptors, which was approximately 1.65 regardless of exogenous Ga o1 expression. Thus, the major difference between the D-301:D-264 efficacy ratio in D 3 -CHO cells compared to mouse striatum appears to be D 3 receptor expression level, which could be addressed in future studies by progressively reducing D 3 receptor expression in the CHO cell model using an irreversible antagonist. This treatment would be expected to disproportionately suppress the efficacy of D-264 relative to that of D-301. It is known that decreases in receptor expression levels disproportionally suppress the relative efficacy of low compared to high efficacy ligands, as has been seen with mu opioid [12] and other GPCRs [49] [50] [51] . Nonetheless, because results in both the striatum of D 3 KO mice and transfected CHO cells (when taking into account the intrinsic efficacy calculation) indicated that D301 is more efficacious than D264 to activate G-proteins via D 3 receptors, we can therefore reject the null hypothesis that D301 and D264 are equally efficacious as D 3 agonists.
Considering the important role of receptor expression density in the determination of ligand efficacy, it is interesting that maximal stimulation of [ 35 S]GTPcS binding in absolute terms was similar between cells expressing D 2 and D 3 receptors with B max values of \1 and [7 pmol/mg, respectively. This discrepancy between receptor density and G protein activation magnitude probably derives from the low efficiency of D 3 receptor-G-protein coupling, as previously reported [9, 34, 52] The low efficiency of D 3 -mediated G protein activation could be related to its reportedly rigid conformation, which also imparts lesser sensitivity of agonist binding affinity to guanine nucleotides [53] [54] [55] . Interestingly, despite the reported low efficiency of D 3 receptor-mediated activation of Ga i/o proteins, this receptor seems to be more promiscuously coupled to activation of multiple Ga families, including Ga s [56, 57] and Ga q [9] , relative to other D 2 -like receptor family members. It will be of interest in future studies to determine whether the efficacy relationship between D301 and D264 is similar for activation of these other Ga types.
In conclusion, the present study revealed differential intrinsic efficacies for D 3 receptor-mediated G protein activation between two chemically similar synthetic ligands, with D-301 showing greater efficacy than D-264. In contrast, these two ligands showed similar efficacy to activate D 2 receptors. This conclusion is supported by data showing greater E max values of D-301 than D-264 in striatal regions from D 2 KO mice, and greater intrinsic efficacy of D-301 than D-264 in D 3 -expressing CHO cells based on a calculation that accounts for receptor reserve in this model. The higher intrinsic efficacy of D-301 relative to D-264 was not significantly altered by co-expression of exogenous Ga o1 , suggesting that higher D 3 receptor expression and not differential expression of Ga subtypes is the predominant factor underlying the differential relative E max values for G protein activation between the CHO cell model and mouse striatum. These findings suggest caution in interpretation of ligand efficacy determinations from a single model system, particularly when potential receptor reserve for the response is not directly determined.
